Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    banners
    From bottlenecks to breakthroughs

    Human-centred strategies for faster study starts

    More than monitoring whitepaper
    More than monitoring

    How modern monitoring paradigms impact CRA roles

    digital globe network with icons
    Meeting requirements for Joint Clinical Assessments

    A planning guide for health technology developers

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    webinar
    When patients lead: Breaking barriers in ultra-rare disease drug development

    3 March 2026. Register today.

    brain
    Boosting clinical trial success in Alzheimer’s, Parkinson’s and other neurodegenerative diseases

    Watch the webinar.

  • About ICON
    About ICON
    Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Modern reception area at Dublin office
    ICON at a glance

    Delivering successful outcomes across the clinical development lifecycle.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. Insights
  3. Blog
  4. Addressing the inevitable: managing medical device cybersecurity risks

Addressing the inevitable: managing medical device cybersecurity risks

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

JoAnne Bronikowski

Sr. Mgr Regulatory Affairs, ICON plc

Cybersecurity threats are among the fastest growing risks for devices connected to private or public networks. Because of this, regulators, including the US Food and Drug Administration (FDA) and the European Medicines Agency, now require medical device developers to include cybersecurity in risk management programmes for any device that could be connected to a network or another device, whether public or private, wired or wireless. (1, 2, 3)

Network connections potentially expose medical devices to threats from many sources – not just through a local router or server in a hospital or medical office, but from any computer, tablet, smart phone or even smart lightbulb connected to the Internet anywhere in the world. Therefore, regulators view cybersecurity as a shared responsibility.

They expect a risk management plan that incorporates input not only from patients, providers, health facilities and device manufacturers, but also from general information technology (IT) software and hardware developers, Internet service providers and commercial cybersecurity firms.

Regulators require cybersecurity risk management plans to cover the entire life of the device, from development and testing throughout its use by healthcare professionals and/or with patients. Plans should address the gamut of potential threats, including deliberate or accidental disruption of device function, interference with data transfer between devices and servers, and any exposure of private medical data, or patient location or identity.

And because hackers are an inventive lot, cybersecurity plans must be continually updated. Probable future threats should be identified and current threats monitored, and new mitigation strategies adopted. These could include hardware changes or software patches, as well as changes in user operating procedures, as required throughout a device’s life cycle.

All this sounds complicated, and it does require significant expertise. However, the FDA and other organisations, notably the US National Institute of Standards and Technology (4), offer detailed guidance for what should be included in a medical device cybersecurity risk management plan, as briefly described here.

 

Protections to ensure device security

“Defence in depth” is a fundamental concept for ensuring information integrity that should guide any medical device cybersecurity plan. It calls for multiple layers of defence, installed throughout an IT system, that protect against unauthorised entry.

For a connected medical device, protection begins with data encryption, and restrictions on what data could be accessed and by whom. In general, data only should be made available if there is a good reason for it. For example, patients might be able to obtain heart rate information from a pacemaker, but should not be granted access to adjust the device, whereas physicians and technicians might have access to both.

Use of public and private encryption keys, strong unique passwords, positive user identification, user access tracing and access timeouts after a set period of inactivity are additional security layers that should be incorporated into the plan’s design from the outset. These protections should be applied to all types of potential data connections including cellular modems, Wi-Fi, Bluetooth, NFC and even RFID devices, as well as any wired connection such as USB ports or telephone jacks.

In addition to the device itself, the security of any server or other device it connects to, along with any intermediary device, must be addressed. For example, if an insulin pump connects via a cell phone to a server in a physician’s office, the cell phone and Internet connections, as well as the receiving server, should be encrypted and protected against unauthorised use.

More importantly, early consideration should be paid to preventable errors caused by human factors, such as the sharing of passwords.  Finally, physical security, such as keeping servers in a locked room, should be mandatory to protect devices and data.

 

Detection and recovery

Additionally, a cybersecurity plan should include mechanisms for detecting when unauthorised access has occurred. An example includes alarms for unauthorised entry or multiple access attempts, which could indicate an attempted takeover. A responsible party should be appointed to respond to any intrusion as required.

A recovery plan is essential, and recovery features should be built into devices and the ecosystems in which they function. These could include the ability to reboot a device that has been compromised and to recognise authentic drivers for the device. Data backups should be maintained to restore compromised devices. These have been especially useful in cases of ransomware attacks, where hospitals and other organisations have been able to recover needed data from backups after a primary system was encrypted and held for ransom.

 

What the FDA wants

Current FDA advice on cybersecurity is not binding, but does cover specific features of a cybersecurity plan for connected devices, including:

  • Plan for software maintenance and updates, and cybersecurity risk management
  • Identification of assets, threats, vulnerabilities and cybersecurity requirements
  • Assessment of potential threats – updated throughout the device’s lifecycle –  in terms of their impact on device function and their effect on patients
  • Mitigation strategies and procedures for preventing unauthorised access and related harms, and recovering from those that occur
  • Documentation of plan, vulnerability and mitigation assessments, security requirements, risk management, data integrity controls and user instructions

Partnering with organisations that understand the complexity of cybersecurity risks and how to address them, as well as what regulators now require, can help keep your device and its users safe from attacks. For information on how ICON cybersecurity experts can help build the safeguards into your devices and operations, contact us. 
 

(1) Cybersecurity for Networked Medical Devices Containing Off the-Shelf (OTS) Software. FDA, Jan. 14, 2005. 
(2) Content of Premarket Submissions for Management of Cybersecurity in Medical Devices. FDA, October 2, 2014. 
(3) Post-market Management of Cybersecurity in Medical Devices. FDA, Dec. 28, 2016. 
(4) Framework for Improving Critical Infrastructure Cybersecurity, draft version 1.1. National Institute for Standards and Technology, January 10, 2017. 

In this section
In this section
  • Digital Disruption
    • Clinical strategies to optimise SaMD for treating mental health
    • Digital Disruption: Surveying the industry's evolving landscape
    • AI and clinical trials
      • Impact of AI on Outcomes Based Contracting
      • Using AI for site ID and selection
      • Applying AI to manage the risks and costs of postmarketing requirements
      • Integrating AI into Clinical Research: How AI is Enhancing Clinical Development
    • Clinical trial data anonymisation and data sharing
    • Clinical Trial Tokenisation
    • Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
    • mHealth wearables
      • Cybersecurity
      • Digital Endpoints
    • Personalising Digital Health
    • Real World Data
      • Harnessing technology to maximise Real World Evidence value
      • Meeting Evidentiary Needs with EHRs
      • Post-Market Surveillance for Medical Devices
    • The triad of trust: Navigating real-world healthcare data integration
    • Decoding AI in software as a medical device (SaMD)
    • Software as a medical device (SaMD)
      • Developing AI in SaMD
  • Patient Centricity
    • Accelerating clinical development through DHTs
    • Agile Clinical Monitoring
    • Capturing the voice of the patient in clinical trials
    • Charting the Managed Access Program Landscape
    • Representation and inclusion in clinical trials
      • Diversity and inclusion in clinical trials whitepaper
    • Exploring the patient perspective from different angles
    • Patient safety and pharmacovigilance
      • A guide to safety data migrations
      • Taking safety reporting to the next level with automation
      • Outsourced Pharmacovigilance Affiliate Solution
      • The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
      • Sponsor and CRO pharmacovigilance and safety alliances
      • Understanding the Periodic Benefit-Risk Evaluation Report
    • Patient voice survey
    • Patient Voice Survey - Decentralised and Hybrid Trials
    • Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
    • Using longitudinal qualitative research to capture the patient voice
    • Prioritising patient-centred research for regulatory approval
  • Regulatory Intelligence
    • Accelerating access
    • Meeting requirements for Joint Clinical Assessments
    • Navigating the regulatory landscape in the US and Japan:
    • Preparing for ICH GCP E6(R3) implementation
    • An innovative approach to rare disease clinical development
    • EU Clinical Trials Regulation
      • EMA guideline on computerised systems and electronic data in clinical trials
      • EU CTR Whitepaper
    • Using innovative tools and lean writing processes to accelerate regulatory document writing
    • Current overview of data sharing within clinical trial transparency
    • Global Agency Meetings: A collaborative approach to drug development
    • Keeping the end in mind: key considerations for creating plain language summaries
    • Navigating orphan drug development from early phase to marketing authorisation
    • Procedural and regulatory know-how for China biotechs in the EU
    • RACE for Children Act
    • Early engagement and regulatory considerations for biotech
    • Regulatory Intelligence Newsletter
    • Requirements & strategy considerations within clinical trial transparency
    • Spotlight on regulatory reforms in China
    • Demystifying EU CTR, MDR and IVDR
    • Transfer of marketing authorisation
    • Exploring FDA guidance for modern Data Monitoring Committees
    • Streamlining dossier preparation
  • Therapeutics insights
    • Endocrine and Metabolic Disorders
    • Cardiovascular
      • Mitigating the impact of COVID-19 on cardiovascular trials
    • Cell and Gene Therapies
      • Approaching the CAR T-cell therapy horizon
      • Cell and Gene ebook
      • Long-term follow-up studies of cell and gene therapies
      • Mainstreaming Cell & Gene Therapies
    • Central Nervous System
      • A mind for digital therapeutics
      • Challenges and opportunities in traumatic brain injury clinical trials
      • Challenges and opportunities in Parkinson’s Disease clinical trials
      • Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D
      • Key Considerations in Chronic Pain Clinical Trials
      • ICON survey report: CNS therapeutic development
    • Glycomics
    • Infectious Diseases
      • Antimicrobial Resistance
      • Considerations for strengthening vaccine development
      • COVID-19 vaccine trials
      • COVID-19 vaccines: Post-authorisation safety surveillance
      • HIV
      • The value of dynamic transmission models
    • NASH
      • The voice of NASH investigators
    • Obesity
      • Addressing obesity's impact across the disease spectrum
      • Trends and challenges in obesity research and clinical trials
      • Obesity and beyond: embracing multi-indication potential during clinical development
      • Survey report: How today’s obesity developers are navigating a multi-indication landscape
    • Oncology
      • ICON survey report: Innovation in Oncology
      • De-risking clinical development of precision medicines in oncology
      • Advances in imaging biomarkers: Estimating drug efficacy with tumour growth rate modelling
      • The future of oncology biosimilars
    • Paediatrics
      • Paediatric Risk Assessment Map
    • Respiratory
    • Rare and orphan diseases
      • Advanced therapies for rare diseases
      • Cross-border enrollment of rare disease patients
      • Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
      • Diversity, equity and inclusion in rare disease clinical trials
      • Identify and mitigate risks to rare disease clinical programmes
      • Leveraging historical data for use in rare disease trials
      • Natural history studies to improve drug development in rare diseases
      • Patient Centricity in Orphan Drug Development
      • The key to remarkable rare disease registries
      • Therapeutic spotlight: Precision medicine considerations in rare diseases
  • Transforming Trials
    • Accelerating biotech innovation from discovery to commercialisation
    • Demystifying the Systematic Literature Reviews
    • Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
    • From bottlenecks to breakthroughs
    • Linguistic validation of Clinical Outcomes Assessments
    • More than monitoring
    • Optimising biotech funding
    • Adaptive clinical trials
      • Adaptive Design: The Faster Path to Market
    • Best practices to increase engagement with medical and scientific poster content
    • Decentralised clinical trials
      • Biopharma perspective: the promise of decentralised models and diversity in clinical trials
      • Decentralised and Hybrid clinical trials
      • Practical considerations in transitioning to hybrid or decentralised clinical trials
      • Navigating the regulatory labyrinth of technology in decentralised clinical trials
    • eCOA implementation
    • Blended solutions insights
      • Clinical trials in Japan: An enterprise growth and management strategy
      • How investments in supply of CRAs is better than competing with the demand for CRAs
      • The evolution of FSP: not just for large pharma
      • Embracing a blended operating model
      • Observations in outsourcing: Survey results show a blended future
    • Implications of COVID-19 on statistical design and analyses of clinical studies
    • Improving pharma R&D efficiency
    • Increasing Complexity and Declining ROI in Drug Development
    • Innovation in Clinical Trial Methodologies
    • Partnership insights
      • Exploring partnership culture and its impact on outsourcing and operational strategy
    • Risk Based Quality Management
    • Transforming the R&D Model to Sustain Growth
  • Value Based Healthcare
    • Strategies for commercialising oncology treatments for young adults
    • US payers and PROs
    • Accelerated early clinical manufacturing
    • Cardiovascular Medical Devices
    • CMS Part D Price Negotiations: Is your drug on the list?
    • COVID-19 navigating global market access
    • Ensuring scientific rigor in external control arms
    • Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
    • Health technology assessment
    • Perspectives from US payers
    • ICER’s impact on payer decision making
    • Making Sense of the Biosimilars Market
    • Medical communications in early phase product development
    • Navigating the Challenges and Opportunities of Value Based Healthcare
    • Payer Reliance on ICER and Perceptions on Value Based Pricing
    • Payers Perspectives on Digital Therapeutics
    • Precision Medicine
    • RWE Generation Cross Sectional Studies and Medical Chart Review
    • Survey results: How to engage healthcare decision-makers
    • The affordability hurdle for gene therapies
    • The Role of ICER as an HTA Organisation
    • Integrating openness and precision for competitive advantage
  • Blog
  • Videos
  • Webinar Channel

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

Related Information

Whitepaper

Cyber Security Checklist

Webpage

Medical Device

Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2026 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?
  • All
  • Website
Popular search terms:
  • Biotech
  • Cell and Gene Therapies
  • Consulting
  • Early Clinical
  • Medical Device
  • Oncology
  • Rare & Orphan Diseases
  • Real World Evidence
  • Site & Patient Recruitment
  • Strategic Solutions
  • Regulatory Intelligence